Literature DB >> 33829569

Marijuana Use Among Adult Liver Transplant Candidates and Recipients.

Alisa Likhitsup1, Naba Saeed1, Gerald Scott Winder2,3, Ammar Hassan1, Christopher J Sonnenday3, Robert J Fontana1.   

Abstract

BACKGROUND: Data regarding marijuana (MJ) use among liver transplant (LT) candidates are limited. We set out to determine the incidence and pre- and post-LT outcomes of adult LT candidates with a self-reported history of MJ use.
METHODS: Baseline clinical characteristics, waitlist, and post-LT outcomes of adult LT candidates from January 2010 to March 2017 were compared.
RESULTS: Amongst 2,690 LT candidates, 630(23%) and 298(11%) reported a history of MJ use and use within the past 12 months, respectively. Although the proportion of MJ users increased over time(β=0.76, p=0.03), the proportion listed and transplanted did not change. Listing for LT increased with male (OR 1.24, 95%CI 11.01-1.52), MELD score (OR 1.08, 95%CI 1.01-1.15), HCC (OR 1.83, 95%CI 1.39-2.41) but decreased among MJ users (OR 0.67, 95%CI 0.50-0.91, p=0.01). The median time to listing was longer among MJ users compared to non-users (115 vs 87 days, p < 0.0005). Post-LT survival was similar in 83 MJ users and 306 non-users.
CONCLUSION: The proportion of MJ users among LT candidates is increasing. MJ users have a greater burden of psychosocial issues which may contribute to longer evaluations and lower rate of LT listing. Post-LT survival was not impacted by self-reported MJ use history. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  and substance use disorder; liver disease; liver transplantation; marijuana; psychosocial evaluation

Year:  2021        PMID: 33829569     DOI: 10.1111/ctr.14312

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  1 in total

1.  Integrated Care of Alcohol-Related Liver Disease.

Authors:  Gerald S Winder; Anne C Fernandez; Jessica L Mellinger
Journal:  J Clin Exp Hepatol       Date:  2022-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.